Publication: Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C
No Thumbnail Available
Date
2011-01-01T00:00:00Z
Authors
Authors
Canbakan, Mustafa
Senturk, HAKAN
Canbakan, Billur
TOPTAŞ, TAYFUR
Tabak, Omur
Ozaras, Resat
Tabak, Fehmi
Balci, Huriye
Sut, Necdet
Ozbay, Gulsen
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Background: Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. Our purpose was to compare the accuracy of the FibroTest (FT) and ActiTest (AT) with liver biopsy and the AST-to-platelet ratio index (APRI) in determining hepatic fibrosis and necroinflammatory activity in hemodialysis patients with hepatitis C virus (HCV). Methods: The FT-AT index combining 6 biochemical markers was assessed in 33 hemodialysis patients with HCV. Liver fibrosis and necroinflammatory activity was staged and graded according to the METAVIR scoring system. Results: The accuracy of FT-AT versus biopsy was 0.46 for significant fibrosis and 0.36 for severe necroinflammatory activity. The FT index had a positive predictive value of 20% for scores greater than 0.6 and a negative predictive value of 45% for scores less than 0.2. Eleven of the 33 patients had scores 0.6 had mild fibrosis. APRI correlated well with the biopsy. Conclusion: The FT-AT test does not seem to be a reliable noninvasive marker for the prediction of necroinflammatory activity and fibrosis in hemodialysis patients with HCV and cannot be used as an alternative to either liver biopsy or APRI. Copyright (C) 2010 S. Karger AG, Basel
Description
Keywords
Citation
Canbakan M., Senturk H., Canbakan B., TOPTAŞ T., Tabak O., Ozaras R., Tabak F., Balci H., Sut N., Ozbay G., -Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C-, NEPHRON CLINICAL PRACTICE, cilt.117, 2011